Figure 1.

CABA-201 shows potent and specific cytotoxicity toward CD19⁺ cells

(A) Characterization of CABA-201 and donor-matched FMC63 CAR T cells generated using a clinical-scale manufacturing process used in subsequent assays. Representative images from one donor are shown. (B) Effector cells (CABA-201, FMC63 CAR T, or NTD) were co-incubated with target Nalm6 cells for 120 h at indicated E:T ratios to measure specific cytotoxicity against CD19⁺ target Nalm6 cells expressing GFP. Cell death is indicated by the decrease in GFP⁺ count, shown as mean ± SD in triplicates. Representative graphs are shown for a healthy donor (HD) and SLE donor. Similar results were obtained from the other donors. (C) Area under the curve (AUC) is shown as mean ± SD from graphs in (B) and from the other donors (n = 4). (D) IFNγ, TNFα, IL-2, and GM-CSF production by CAR T cells in the supernatants collected after 24 h of CABA-201 from four donors co-cultured with CD19⁺ Nalm6 cells is shown. Donor-matched NTD and FMC63 CAR T cells were used. Each bar represents mean ± SD of four different donors. Statistical differences between CABA-201 and FMC63 CAR T cells were determined by two-way ANOVA with Tukey’s multiple comparisons test. ∗∗∗∗p ≤ 0.0001, ∗∗∗p ≤ 0.001, ∗∗p ≤ 0.01, ∗p ≤ 0.05, ns = not significant. Experiments were repeated two times independently.